The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

PKC alpha expression is a marker for breast cancer aggressiveness

På svenska

Author

Summary, in English

Background: Protein kinase C (PKC) isoforms are potential targets for breast cancer therapy. This study was designed to evaluate which PKC isoforms might be optimal targets for different breast cancer subtypes. Results: In two cohorts of primary breast cancers, PKC alpha levels correlated to estrogen and progesterone receptor negativity, tumor grade, and proliferative activity, whereas PKC delta and PKC epsilon did not correlate to clinicopathological parameters. Patients with PKC alpha-positive tumors showed poorer survival than patients with PKC alpha-negative tumors independently of other factors. Cell line studies demonstrated that PKC alpha levels are high in MDA-MB-231 and absent in T47D cells which proliferated slower than other cell lines. Furthermore, PKC alpha silencing reduced proliferation of MDA-MB-231 cells. PKC alpha inhibition or downregulation also reduced cell migration in vitro. Conclusions: PKC alpha is a marker for poor prognosis of breast cancer and correlates to and is important for cell functions associated with breast cancer progression.

Publishing year

2010

Language

English

Publication/Series

Molecular Cancer

Volume

9

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Pathology, Malmö

ISBN/ISSN/Other

  • ISSN: 1476-4598